MiMedx Group (NASDAQ:MDXG) Sets New 1-Year Low – Here’s What Happened

MiMedx Group, Inc (NASDAQ:MDXG)’s share price reached a new 52-week low on Friday . The stock traded as low as $4.35 and last traded at $4.3550, with a volume of 156572 shares changing hands. The stock had previously closed at $4.38.

Analyst Ratings Changes

Several research analysts have recently issued reports on MDXG shares. Cantor Fitzgerald decreased their target price on MiMedx Group from $12.00 to $8.00 and set an “overweight” rating for the company in a research report on Tuesday, February 17th. Wall Street Zen cut MiMedx Group from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 28th. Weiss Ratings reiterated a “hold (c)” rating on shares of MiMedx Group in a report on Monday, December 29th. Citigroup began coverage on shares of MiMedx Group in a report on Monday, February 23rd. They set a “market outperform” rating on the stock. Finally, Citizens Jmp initiated coverage on shares of MiMedx Group in a research note on Monday, February 23rd. They issued a “market outperform” rating and a $10.00 price target for the company. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, MiMedx Group currently has a consensus rating of “Moderate Buy” and an average price target of $9.60.

MiMedx Group Price Performance

The firm has a fifty day moving average price of $5.28 and a two-hundred day moving average price of $6.42. The company has a quick ratio of 3.92, a current ratio of 4.32 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $647.02 million, a P/E ratio of 13.61 and a beta of 1.60.

MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings results on Wednesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.05. The company had revenue of $118.10 million for the quarter, compared to analysts’ expectations of $106.78 million. MiMedx Group had a net margin of 11.60% and a return on equity of 29.37%. On average, analysts expect that MiMedx Group, Inc will post 0.3 EPS for the current year.

Institutional Trading of MiMedx Group

A number of institutional investors and hedge funds have recently modified their holdings of the business. Trigran Investments Inc. lifted its holdings in shares of MiMedx Group by 10.4% during the second quarter. Trigran Investments Inc. now owns 8,390,458 shares of the company’s stock valued at $51,266,000 after purchasing an additional 790,901 shares in the last quarter. Vanguard Group Inc. raised its position in MiMedx Group by 5.6% in the 4th quarter. Vanguard Group Inc. now owns 7,184,262 shares of the company’s stock worth $48,637,000 after buying an additional 382,623 shares during the last quarter. State Street Corp lifted its stake in MiMedx Group by 6.1% during the 4th quarter. State Street Corp now owns 3,813,796 shares of the company’s stock valued at $25,819,000 after acquiring an additional 219,190 shares during the period. First Light Asset Management LLC lifted its stake in MiMedx Group by 89.5% during the 3rd quarter. First Light Asset Management LLC now owns 3,652,952 shares of the company’s stock valued at $25,498,000 after acquiring an additional 1,725,458 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of MiMedx Group by 4.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,479,369 shares of the company’s stock valued at $16,786,000 after acquiring an additional 97,036 shares during the last quarter. Institutional investors own 79.15% of the company’s stock.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.